
export const drugData=[{
    "cid":"D001",
  "marketInformation": {
    "brandName": "Xalkori",
    "indication": "ALK- or ROS1-positive non‑small cell lung cancer (NSCLC), as well as certain forms of ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumors (IMT)",
    "approvedFor": "Pfizer Inc.",
    "approvedCountries": "Globally approved in more than 90 countries. Approved in the US and EU.",
    "approvedDate": "2011",
    "genericName": "Generic not available yet",
    "genericApprovedDate": "N/A",
    "potentialGenericAvailability": "Nov, 2029 (based on patent expiration, this can change based on legal challenges and licensing agreements.)",
    "specialStatus": "Orphan Drug Designation available for pediatric ALCL treatment until Jan 14, 2028",
    "patentExclusivityInfo": "",
    "References": ""
  },
  "drugSubstance": {
    "physicalAndChemicalProperties": {
      "chemicalName": "Crizotinib",
      "chemicalStructure": "See media/image1.png",
      "potencyClassification": "",
      "elementalFormula": "C21H22Cl2FN5O",
      "bcsClass": "Class IV (low solubility and low permeability)",
      "molecularWeight": "450.3 g/mol",
      "averageIsotopicMass": "449.11854397 g/mol",
      "structureName": "(R)-3-[1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine",
      "solubility": "Insoluble in water. Solubility decreases as pH increases, dropping from >10 mg/mL at pH 1.6 to <0.1 mg/mL at pH 8.2.",
      "pka": "Has two pKa values: 9.4 (piperidinium cation) and 5.6 (pyridinium cation).",
      "logp": "The partition coefficient (octanol/water) at pH 7.4 is 1.65.",
    "References": ""
    },
    "processDevelopment": {
      "availableDmfVendors": [
        "LGM Pharma",
        "Chongqing Huapont Pharmaceutical",
        "Navinta",
        "Wuxi further pharmaceutical CO"
      ],
      "vendorReference": "http://pharmacompass.com/manufacturers-suppliers-exporters/crizotinib",
      "potencyClassification": "",
      "manufacturingSites": [
        {
          "vendor": "LGM Pharma",
          "location": "USA"
        },
        {
          "vendor": "Chongqing Huapont Pharmaceutical",
          "location": "China"
        },
        {
          "vendor": "Navinta",
          "location": "USA"
        }
      ],
      "manufacturingRoute": "See Appendix 1",
      "polymorphStudies": "Only one crystalline form has been found, thermodynamically stable form A",
      "regulatoryStartingMaterials": "",
      "rsmAndIntermediateSpecifications": "",
      "drugSubstanceSpecifications": "Appendix 2: DS Specification",
      "forcedDegradationStudies": "Stress studies were performed at high temperatures, and no significant degradation was observed after 14 days stored at 100°C. Minor degradation was observed when crizotinib was exposed to strongly acidic, strongly basic, intense light and oxidative conditions.",
      "impurityQualification": "",
      "genotoxicImpuritiesAssessment": "",
      "nitrosaminesAssessment": "",
      "fateOfImpurities": "",
      "cppsAndCqaStudies": "",
      "otherInformation": "",
    "References": ""
    },
    "analyticalDevelopment": {
      "rsmMethods": "",
      "ipcTestMethods": "",
      "finalApiMethods": "",
      "residualSolventRiskAssessment": "",
      "rsmSynthesis": "",
      "stabilityOfDrugSubstance": "",
      "drugSubstanceSites": "Manufacturing, Analytical Testing and Release are performed at: Pfizer Ireland Pharmaceuticals Little Island County Cork Ireland",
      "dsImpurities": "",
      "dsImpurityMethods": "",
    "References": ""
    }
  },
  "drugProduct": {
    "information": {
      "dosageForms": "Capsules, Oral pellets(encapsulated)",
      "strengths": [
        {
          "strength": "200 mg",
          "description": "hard gelatin capsule, size 1, white opaque body and pink opaque cap, with 'Pfizer' on the cap and 'CRZ 200' on the body.",
          "type": "capsule"
        },
        {
          "strength": "250 mg",
          "description": "hard gelatin capsule, size 0, pink opaque cap and body, with 'Pfizer' on the cap and 'CRZ 250' on the body.",
          "type": "capsule"
        },
        {
          "strength": "20 mg",
          "description": "Oral Pellets: hard gelatin capsule, size 4, white opaque body and light blue opaque cap, printed with black ink 'Pfizer' on the cap and 'CRZ 20' on the body.",
          "type": "oral_pellets"
        },
        {
          "strength": "50 mg",
          "description": "Oral Pellets: hard gelatin capsule, size 3, light gray opaque body and gray opaque cap, printed with black ink 'Pfizer' on the cap and 'CRZ 50' on the body.",
          "type": "oral_pellets"
        },
        {
          "strength": "150 mg",
          "description": "Oral Pellets: hard gelatin capsule, size 0, light blue opaque body and cap, printed with black ink 'Pfizer' on the cap and 'CRZ 150' on the body.",
          "type": "oral_pellets"
        }
      ],
      "targetPopulation": "Adults",
      "maximumDailyDose": "1000 mg, 2*250 mg capsules taken twice daily",
      "storageAndShippingConditions": "USP CRT",
      "developmentProgramDesignation": "Xalkori (crizotinib) received multiple developmental program designations from the FDA for different indications, including Breakthrough Therapy, Orphan Drug, Fast Track, Priority Review, and Accelerated Approval. Appendix 3",
      "dpFormulation": "",
      "unmetClinicalNeed": "",
      "manufacturingProcess": "",
      "excipientsgGrade": "",
      "impurities": "",
      "specification": "",
      "testMethods": "",
      "residualSolventsRiskAssessment": "",
      "nitrosamineRiskAssessment": "",
      "stabilityStudies": "",
      "dissolutionStudies": "",
      "baBeStudies": "",
      "foodStudyReports": "",
      "currentLabel": "",
      "dpEmbossingDebossingInfo": "",
      "currentExpirationDating": {
        "oralPellets": "24 months from the date of manufacture",
        "capsules": "15 months from the date of manufacture when first approved by the FDA in 2011. The specific expiration for a particular bottle can be found printed on the outer package."
      },
      "foodInteractions": [
        "Avoid grapefruit products. Grapefruit inhibits CYP3A4 metabolism, which may increase the serum levels of crizotinib.",
        "Take with or without food. High-fat food decreases drug absorption, but not to a clinically significant extent."
      ],
      "drugDrugInteractions": [
        "Avoid St. John's Wort. This herb induces CYP3A4 metabolism, which may reduce serum levels of crizotinib."
      ],
      "packagingAndStorageConditions": {
        "200mg": {
          "description": "Hard gelatin capsule with pink opaque cap and white opaque body, printed with black ink 'Pfizer' on the cap, 'CRZ 200' on the body",
          "packaging": "Bottles of 60 capsules: NDC 0069-8141-20",
          "type": "capsules",
          "storageTemperature": "Store at room temperature 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]."
        },
        "250mg": {
          "description": "Hard gelatin capsule with pink opaque cap and body, printed with black ink 'Pfizer' on the cap, 'CRZ 250' on the body",
          "packaging": "Bottles of 60 capsules: NDC 0069-8140-20",
          "type": "capsules",
          "storageTemperature": "Store at room temperature 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]."
        },
        "20mg": {
          "description": "Hard gelatin capsule, size 4, light blue opaque cap and white opaque body, printed with black ink 'Pfizer' on the cap, 'CRZ 20' on the body",
          "packaging": "Bottles of 60 capsules: NDC 0069-0251-60",
          "type": "oral_pellets",
          "storageTemperature": "Store at room temperature 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]."
        },
        "50mg": {
          "description": "Hard gelatin capsule, size 3, gray opaque cap and light gray opaque body, printed with black ink 'Pfizer' on the cap, 'CRZ 50' on the body",
          "packaging": "Bottles of 60 capsules: NDC 0069-0507-60",
          "type": "oral_pellets",
          "storageTemperature": "Store at room temperature 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]."
        },
        "150mg": {
          "description": "Hard gelatin capsule, size 0, light blue opaque cap and body, printed with black ink 'Pfizer' on the cap, 'CRZ 150' on the body",
          "packaging": "Bottles of 60 capsules: NDC 0069-1500-60",
          "type": "oral_pellets",
          "storageTemperature": "Store at room temperature 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]."
        },
        
      },
      "labeling": "Appendix 4: Labeling Information",
      "developmentProgramDesignationDetails": "Appendix 5: Development program designation",
    "References": ""
    }
  },

  "appendices": {
    "appendix1":{
      
      "name": "API Synthetic Route",
      "reference": "https://pubs.acs.org/doi/10.1021/acs.oprd.0c00302",
      "description": "Crizotinib API is manufactured through a stepwise synthetic organic chemistry process that constructs the pyrazole and pyridine rings separately, joins them via ether linkage to the dichloro-fluoroaryl group, and resolves the final product to the R-enantiomer. Manufacturing emphasizes chiral control, impurity management, and recrystallization for purity.",
      "modularSynthesis": {
        "overview": "The synthesis is modular, built from heteroaryl intermediates:",
        "steps": [
          {
            "name": "Pyrazole Core Formation",
            "details": [
              "Constructed from hydrazine derivatives + diketone or equivalent starting materials.",
              "Functionalization introduces the piperidin-4-yl substituent."
            ]
          },
          {
            "name": "Pyridine Intermediate",
            "details": [
              "Prepared via nucleophilic substitution and amination chemistry.",
              "Introduces the amine group at the 2-position."
            ]
          },
          {
            "name": "Ether Coupling",
            "details": [
              "Key step: O-alkylation (ether formation) between the pyridine ring and the dichloro-fluorophenyl moiety.",
              "Typically achieved under basic conditions with appropriate leaving groups."
            ]
          },
          {
            "name": "Chiral Resolution / Enantioselective Step",
            "details": [
              "The API used in Xalkori is the R-enantiomer.",
              "Resolution achieved either by:",
              "Chiral chromatography, or",
              "Diastereomeric salt formation and recrystallization, depending on scale."
            ]
          },
          {
            "name": "Final Purification & Salt Form",
            "details": [
              "API is isolated as crizotinib free base (not a salt form).",
              "Purified by recrystallization, meeting ICH impurity thresholds."
            ]
          },
          {
            "name":"Crizotinib (PF-02341066) | Route overview",
            "details": ["3-position ether on pyridine via Mitsunobu from the benzylic alcohol",
          "5-position aryl–aryl bond via Suzuki–Miyaura to install the pyrazol-4-yl-piperidin-4-yl fragment",
          "Nitro → amine reduction on the pyridine core (gives the 2-amine)"],
          }
        ]
      },
      "processDocumentation": "Pfizer's published process-development paper plus process patents that describe scalable conditions.",
      "synthesisSteps": [
        {
          "step": "A",
          "title": "Chiral benzylic alcohol",
          "description": "Prepare (S)-1-(2,6-dichloro-3-fluorophenyl)ethanol (enantiopure). In Pfizer's enabling route the downstream Mitsunobu inverts this center, delivering the (R) configuration in the API.",
          "links": [
            "https://www.researchgate.net/publication/278699491_Fit-for-Purpose_Development_of_the_Enabling_Route_to_Crizotinib_PF-02341066?utm_source=chatgpt.com"
          ]
        },
        {
          "step": "B",
          "title": "Mitsunobu etherification (installs the 3-ethoxy)",
          "description":"substrates: 5-bromo-3-hydroxy-2-nitropyridine + (S)-benzylic alcohol,conditions: Typical conditions (scaleable): PPh₃ / DIAD, toluene, 0--25 °C → then EtOH crystallization to purge TPPO; delivers 5-bromo-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-2-nitropyridine in ~80--90% yield with retained ee after inversion.yield: ~80--90% yield with retained ee after inversion,",
          "links": [
            "https://www.researchgate.net/publication/278699491_Fit-for-Purpose_Development_of_the_Enabling_Route_to_Crizotinib_PF-02341066?utm_source=chatgpt.com",
            "https://pmc.ncbi.nlm.nih.gov/articles/PMC8173612/?utm_source=chatgpt.com",
            "https://pubs.acs.org/doi/10.1021/acsomega.1c01996?utm_source=chatgpt.com",
            "https://patents.google.com/patent/US9604966B2/en?utm_source=chatgpt.com"
          ]
        },
        {
          "step": "C",
          "title": "Chemoselective nitro → amine reduction (builds the 2-amine)",
          "description":"method: Hydrogenation (H₂, sponge-Ni or Raney-Ni, MeOH, ambient--40 °C) converts the nitro to give (R)-5-bromo-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-2-amine.,product: (R)-5-bromo-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-2-amine (CAS 877399-00-3)",
          "links": [
            "https://www.lookchem.com/casno877399-52-5.html?utm_source=chatgpt.com",
            "https://www.ruifuchemical.com/cas-877399-00-3-product/?utm_source=chatgpt.com"
          ]
        },
        {
          "step": "D",
          "title": "Pyrazolyl-piperidine boron partner",
          "description": "Prepare 1-(1-Boc-4-piperidinyl)-1H-pyrazol-4-yl boronic acid/ester. This is the coupling partner for the 5-bromo pyridinamine.",
          "links": [
            "https://www.ruifuchemical.com/cas-877399-00-3-product/?utm_source=chatgpt.com",
            "https://patents.google.com/patent/US9604966B2/en?utm_source=chatgpt.com"
          ]
        },
        {
          "step": "E",
          "title": "Suzuki--Miyaura at C-5 of pyridine",
          "description":"substrates: (R)-5-bromo pyridin-2-amine (from Step C) + Boc-protected pyrazolyl-piperidinyl boronic acid,conditions: Representative conditions: Pd(PPh₃)₄, Na₂CO₃ (aq), DMF/H₂O, ∼60 °C, giving the Boc-protected crizotinib precursor in high yield, chromatography-free.",
          "links": [
            "https://patents.google.com/patent/US9604966B2/en?utm_source=chatgpt.com",
            "https://commonorganicchemistry.com/Rxn_Pages/Suzuki/Suzuki.htm?utm_source=chatgpt.com"
          ]
        },
        {
          "step": "F",
          "title": "Global deprotection / finish",
          "description":"method: Acidolysis of Boc (e.g., HCl/EtOH or HCl/dioxane) → neutralization/recrystallization to the free base crizotinib.",
          "links": [
            "https://patents.google.com/patent/US9604966B2/en?utm_source=chatgpt.com",
            "https://www.ema.europa.eu/en/documents/assessment-report/xalkori-epar-public-assessment-report_en.pdf?utm_source=chatgpt.com"
          ]
        },{
            "step": "G",
            "title":"Why this is the industrial route",
            "description":"Chiral center control: single inversion at Mitsunobu gives the desired (R) configuration with no racemization; ee is preserved through downstream steps.Robust scale-ups: chromatography-free EtOH crystallizations purge TPPO; sponge-Ni H₂ reduction and Suzuki run cleanly at moderate T.  Proven at >100 kg scale in Pfizer’s process-development report.",
            "links":[
                "https://www.researchgate.net/publication/278699491_Fit-for-Purpose_Development_of_the_Enabling_Route_to_Crizotinib_PF-02341066?utm_source=chatgpt.com",
                "https://pmc.ncbi.nlm.nih.gov/articles/PMC8173612/?utm_source=chatgpt.com",
                "https://pubs.acs.org/doi/10.1021/op200131n?utm_source=chatgpt.com"
            ]
        }
      ],
      
      "currentManufacturers": "Pfizer sites across the globe"
    },
    "appendix2":{      "name": "DS Specification",
      "specifications": {
        "description": "A white pale-yellow powder. Non-hygroscopic",
        "assay": "",
        "relatedSubstances": "",
        "chiral": "",
        "polymorph": "Amorphous form is used",
        "idByHplc": "",
        "idByFtir": "",
        "particleSizeDistribution": "",
        "residueOnIgnition": "",
        "heavyMetals": "",
        "palladium": "Limit set as per EMA/CHMP/SWP/4666/2000 Option 2a"
      }
    },
    "appendix3":{
            "name": "Formulation Composition",
      "note": "All excipients used in the formulation are compendial and conventional for solid oral dosage forms.",
      "inactiveIngredients": [
        { "ingredientName": "SILICON DIOXIDE (UNII: ETJ7Z6XBU4)", "strength": "" },
        { "ingredientName": "MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)", "strength": "" },
        { "ingredientName": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE (UNII: L11K75P92J)", "strength": "" },
        { "ingredientName": "MAGNESIUM STEARATE (UNII: 70097M6I30)", "strength": "" },
        { "ingredientName": "GELATIN, UNSPECIFIED (UNII: 2G86QN327L)", "strength": "" },
        { "ingredientName": "TITANIUM DIOXIDE (UNII: 15FIX9V2JP)", "strength": "" },
        { "ingredientName": "FERRIC OXIDE RED (UNII: 1K09F3G675)", "strength": "" },
        { "ingredientName": "SHELLAC (UNII: 46N107B71O)", "strength": "" },
        { "ingredientName": "PROPYLENE GLYCOL (UNII: 6DC9Q167V3)", "strength": "" },
        { "ingredientName": "AMMONIA (UNII: 5138Q19F1X)", "strength": "" },
        { "ingredientName": "POTASSIUM HYDROXIDE (UNII: WZH3C48M4T)", "strength": "" },
        { "ingredientName": "FERROSOFERRIC OXIDE (UNII: XM0M87F357)", "strength": "" },
        { "ingredientName": "SODIUM STARCH GLYCOLATE TYPE A (UNII: H8AV0SQX4D)", "strength": "" }
      ]
    },
    "appendix4":{
      
      "name": "Labeling Information",
      "labels": [
        { "label": "250 mg Capsule Bottle", "image": "image2" },
        { "label": "200 mg Capsule Bottle", "image": "image3" },
        { "label": "20 mg Oral Pellets", "image": "image4" },
        { "label": "50 mg Oral Pellets", "image": "image5" },
        { "label": "150 mg Oral Pellets", "image": "image6" }
      ]
    },
    "appendix5":{
            "name": "Development Program Designation",
      "description": "Xalkori (crizotinib) received multiple developmental program designations from the FDA for different indications, including Breakthrough Therapy, Orphan Drug, Fast Track, Priority Review, and Accelerated Approval.",
      "designations": {
        "Breakthrough Therapy": [
          "ROS1-positive non-small cell lung cancer (NSCLC): In April 2015, the FDA granted Breakthrough Therapy status for Xalkori in treating patients with ROS1-positive NSCLC.",
          "MET exon 14 alterations: In May 2018, Xalkori received Breakthrough Therapy designation for treating patients with metastatic NSCLC who have MET exon 14 alterations.",
          "ALK-positive anaplastic large cell lymphoma (ALCL): At the same time in May 2018, it also received this designation for treating relapsed or refractory ALK-positive ALCL."
        ],
        "Orphan Drug": [
          "Anaplastic lymphoma kinase (ALK)-positive NSCLC: This designation was given in September 2010 to encourage the development of the drug for this rare form of lung cancer.",
          "ALK-positive anaplastic large cell lymphoma (ALCL): In September 2012, Xalkori was designated as an Orphan Drug for ALCL.",
          "ALK-positive inflammatory myofibroblastic tumor (IMT): The FDA also granted this designation for treating ALK-positive IMT."
        ],
        "Fast Track": [
          "ALK-positive advanced NSCLC: This designation was given in December 2010 to expedite the review of Xalkori for patients with ALK-positive NSCLC."
        ],
        "Accelerated Approval and Priority Review": [
          "ALK-positive NSCLC: The FDA granted accelerated approval for Xalkori for ALK-positive NSCLC in August 2011, reflecting the drug's potential for a serious condition.",
          "ROS1-positive NSCLC: In March 2016, the FDA approved Xalkori for ROS1-positive NSCLC and granted the application Priority Review status."
        ]
      }
    }
  },


  "references": [
    {
      "title": "Pfizer OPRD process paper (six-step enabling route; Mitsunobu ↔ Suzuki ↔ H₂/Ni): de Koning et al. 2011.",
      "url": "https://pubs.acs.org/doi/10.1021/op200131n"
    },
    {
      "title": "Process patent with explicit conditions (Mitsunobu in THF/toluene; Suzuki in DMF/Na₂CO₃; Boc deprotection HCl/EtOH): US 9,604,966.",
      "url": "https://patents.google.com/patent/US9604966B2/en"
    },
    {
      "title": "J. Med. Chem. chemistry note (Mitsunobu of 5-bromo-3-hydroxy-2-nitropyridine alcoholates to intermediates): design paper.",
      "url": "https://pubs.acs.org/doi/10.1021/jm401805h"
    },
    {
      "title": "Commercial intermediates listing (confirms structures/CAS used on route): Ruifu Chemical.",
      "url": "https://www.ruifuchemical.com/cas-877399-00-3-product/"
    },
    {
      "title": "EMA EPAR (API as free base in product): Xalkori (crizotinib).",
      "url": "https://www.ema.europa.eu/en/documents/assessment-report/xalkori-epar-public-assessment-report_en.pdf"
    }
  ]
},

]


